These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11447097)

  • 21. Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: still problematic after the primary publication.
    Brinton EA
    J Clin Lipidol; 2012; 6(4):312-7. PubMed ID: 22836067
    [No Abstract]   [Full Text] [Related]  

  • 22. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.
    Kuvin JT; Dave DM; Sliney KA; Mooney P; Patel AR; Kimmelstiel CD; Karas RH
    Am J Cardiol; 2006 Sep; 98(6):743-5. PubMed ID: 16950175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JA; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2002 Oct; 90(7):689-96. PubMed ID: 12356379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The emerging role of HDL cholesterol. Is it time to focus more energy on raising high-density lipoprotein levels?
    Safeer RS; Cornell MO
    Postgrad Med; 2000 Dec; 108(7):87-90, 93-8. PubMed ID: 11126145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Niacin: its value in raising HDL cholesterol is being questioned.
    Heart Advis; 2011 Oct; 14(10):7. PubMed ID: 23019714
    [No Abstract]   [Full Text] [Related]  

  • 29. Practical management of dyslipidemia with elevated lipoprotein(a).
    Riche DM; East HE; Priest HM
    J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
    Boden WE
    Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
    Sprecher DL
    Am J Cardiol; 2000 Dec; 86(12A):46L-50L. PubMed ID: 11374856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated lipoprotein(a) and premature coronary heart disease.
    Parsons WB
    JAMA; 1997 Jan; 277(3):209; author reply 210. PubMed ID: 9005264
    [No Abstract]   [Full Text] [Related]  

  • 34. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.
    Lee JM; Robson MD; Yu LM; Shirodaria CC; Cunnington C; Kylintireas I; Digby JE; Bannister T; Handa A; Wiesmann F; Durrington PN; Channon KM; Neubauer S; Choudhury RP
    J Am Coll Cardiol; 2009 Nov; 54(19):1787-94. PubMed ID: 19874992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous screening for three correlated lipids in the VA HDL Intervention Trial.
    Iwane MK; Wittes J; Collins DE; Rubins HB
    J Clin Epidemiol; 1999 Jul; 52(7):685-93. PubMed ID: 10391662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of raising high-density lipoprotein cholesterol for prevention of coronary heart disease.
    Teramoto T
    Curr Atheroscler Rep; 2002 Sep; 4(5):327-8. PubMed ID: 12162930
    [No Abstract]   [Full Text] [Related]  

  • 38. Time course of serum Lp(a) in men after coronary artery bypass grafting.
    Cobbaert C; Sergeant P; Meyns B; Szécsi J; Kesteloot H
    Acta Cardiol; 1992; 47(6):529-42. PubMed ID: 1290314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.